^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ocifisertib (CFI-400945) (PLK4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
Published date:
12/19/2023
Excerpt:
...13 patients were treated with CFI-400945 continuously in dose escalation from 64 mg/day to 128 mg/day...Three of the 9 efficacy evaluable AML patients achieved complete remission (CR). Two of 4 AML patients (50%) with TP53 mutations and complex monosomal karyotype achieved a CR with 1 patient proceeding to allogenic stem cell transplant.
DOI:
10.1038/s41375-023-02110-9
Trial ID:
Source:
Title:
Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS
Published date:
11/04/2020
Excerpt:
Patient characteristics....somatic mutations...TP53 mutation....Six patients were evaluable for disease response. Two (33%) achieved complete remission (CR)...Single agent CFI-400945 has activity in patients with poor risk AML.
DOI:
https://doi.org/10.1182/blood-2020-138822
